Shares of WW International, formerly WeightWatchers ( NASDAQ: WW ), jumped on Tuesday after it announced a partnership with ...

Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the ...

As President Donald Trump hits 100 days in his second term, the administration is touting the billions of investments ...

The Dow and S&P 500 look to notch a sixth day of gains as investors await more trade news and an easing of tariffs on ...

Novo Nordisk said on Tuesday it was partnering with telehealth firms Hims & Hers , Ro and LifeMD to sell branded versions of ...

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Mr Trump is expected to tout numerous financial commitments his administration has secured Read more at straitstimes.com.

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering ...